Price Alert

Grifols S.A. (GRFS)

NASDAQ: GRFS · Real-Time Price · USD

9.59

0.01 (0.10%)

At close: Oct 15, 2025, 3:59 PM

9.59

0.00%

After-hours: Oct 15, 2025, 04:04 PM EDT

0.10% (1D)

Bid	9.55
Market Cap	8.11B
Revenue (ttm)	7.45B
Net Income (ttm)	297.45M
EPS (ttm)	0.51
PE Ratio (ttm)	18.8
Forward PE	8.75
Analyst	Hold
Dividends	n/a

Ask	9.63
Volume	211,669
Avg. Volume (20D)	845,025
Open	9.58
Previous Close	9.58
Day's Range	9.54 - 9.65
52-Week Range	6.19 - 11.14
Beta	1.02
Ex-Dividend Date	n/a

About GRFS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GRFS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for GRFS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

5 months ago

+8.87%

Grifols shares are trading higher after the compan... Unlock content with Pro Subscription

10 months ago

Grifols shares are trading lower after the company ended discussions with Brookfield Capital Partners regarding a potential acquisition.

News

5 days ago · zacks.com

GRFS vs. STVN: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang fo...

5 days ago · zacks.com

Is Grifols (GRFS) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

6 days ago · reuters.com

Spanish court summons Gotham City founder in Grifols share price probe

Spain's High Court on Thursday summoned the founder of U.S.-based short seller Gotham City Research, Daniel Yu, to testify over allegations his company disseminated misleading information about pharma...

1 week ago · seekingalpha.com

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

1 week ago · seekingalpha.com

Grifols: Significant Upside Likely Materializing

Grifols demonstrates strong recovery, with leverage reduced to 4.2x and dividend reinstated, supporting a renewed investment case. GRFS posted robust Q2 2025 results: 7% revenue growth, 12.5% EBITDA g...

3 weeks ago · zacks.com

GRFS or NBIX: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those ...